HM15136: Clinical Trials

1 trial of HM15136, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

1 active not recruiting. 1 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 21Active not recruiting 1

Follow HM15136: new trials by email Literature Review of HM15136 trials Research Report on HM15136

Trials (filtered) newest first · largest first

All 1 trial

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
HM15136 (Efpegerglucagon) Treatment for 8 Weeks in Subjects Aged ≥2 Years With Congenital Hyperinsulinism (CHI)
HM15136 - Congenital Hyperinsulinism
Phase 2Active not recruitingHanmi Pharmaceutical Company Limited172022-05-052026-08-26

Conditions studied

Congenital Hyperinsulinism (1)

Sponsors

Hanmi Pharmaceutical Company Limited (1)

Countries

Germany (1)  ·  Israel (1)  ·  South Korea (1)  ·  United Kingdom (1)  ·  United States (1)